Zhengxiang Yang,Aibin Zhang,Xiaoyu Lai,Luxin Yang,Yishan Ye,Qingna Guo,Yibo Wu,He Huang,Yi Luo,Lizhen Liu,
Splenectomy before Allogeneic Hematopoietic Stem-cell Transplantation for Myelofibrosis: Two Cases
Surgical Case Reports
2024
2613-5965
http://dx.doi.org/10.31487/j.SCR.2024.02.01
https://www.sciencerepository.org/splenectomy-before-allogeneic-hematopoietic_SCR-2024-2-101 
Abstract: Myelofibrosis (MF) is a clonal hematological malignancy characterized by splenomegaly, systemic symptoms, myelofibrosis, and a tendency to transform into acute leukemia. MF treatment includes anemia treatment, hydroxyurea, JAK inhibitors (JAKi) allogeneic hematopoietic stem cell transplantation (allo-HSCT), among which allo-HSCT is the only possible cure for MF. The effect of splenomegaly on the prognosis of allo-HSCT with myelofibrosis and whether splenic treatment is needed before transplantation has not been determined. A recent retrospective study from the EBMT working group found that splenectomy significantly reduced transplant-related non-recurrent mortality and did not increase the risk of disease recurrence in MF patients with pre-transplant splenomegaly. Two cases of MF splenectomy combined with allo-HSCT are reported.Keywords: Splenectomy, myelofibrosis, massive splenomegaly, allogeneic hematopoietic stem cell transplantation